Arkolith/Insider Trading/SILO/Form 4

Weisblum Eric

Chief Executive Officer, DirectorSilo Pharma, Inc. (SILO) · full profile →Form 4 · filed Nov 20, 2025
Net Buying
Open-Market Buys
$5K
Open-Market Sells
$0
Net Open-Market Flow
$5K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 19, 2025Buy(P)5K$0.41$2K210K
Nov 18, 2025Buy(P)8K$0.40$3K205K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001213900-25-113104) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML